Amend 006 - PERTUSSIS VACCINES - GlaxoSmithKline Inc.
Status Awarded
Contract number E60PH-21PERT/002/PH
Solicitation number E60PH-21PERT
Publication date
Contract award date
Last amendment date
Amendment value
Status Awarded
Contract number E60PH-21PERT/002/PH
Solicitation number E60PH-21PERT
Publication date
Contract award date
Last amendment date
Amendment value
This contract was awarded to:
The contract will be for a period of 50 month(s), from 2021/01/05 to 2025/03/31.
CAD 50,034,497.80
A contracting officer can use limited tendering for specific reasons outlined in the applicable trade agreements. The reason for this contract is described below: